Drug development company Generate Biomedicines experienced a rocky start on Wall Street Friday, with its stock price dropping 6.25% during its first day of trading on the Nasdaq exchange.
The pharmaceutical firm, which receives backing from investment company Flagship, ended its debut trading session with a market value of $1.91 billion. Market analysts attributed the decline to ongoing uncertainty in financial markets that has made investors wary of newly public companies.
The stock’s performance reflects broader market conditions that have made investors more selective about new investment opportunities, particularly in the biotechnology sector.
